Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
741-760 of 3,900 trials

Extrapulmonary Small Cell Carcinoma: Durvalumab Combination Therapy

We are studying a new treatment combining durvalumab with carboplatin or cisplatin and etoposide for patients with extensive stage extrapulmonary small cell carcinoma. The goal is to see if this combination improves survival and quality of life compared to standard treatments.

Extensive Stage Extrapulmonary Small Cell CarcinomaEfficacy phase (II)No PlaceboStandard MedicinesOncology

Pulmonary Arterial Hypertension: Treprostinil Sodium for Kids

We are studying the safety and tolerability of a new preservative-free medication for children with pulmonary arterial hypertension. The trial also looks at how it may improve their quality of life and symptoms.

Pulmonary Arterial Hypertension3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemotePediatricsPulmonology

ASP1570 for Advanced Solid Tumors

We are studying a new treatment, ASP1570, alone and with pembrolizumab for adults with advanced solid tumors. The trial aims to evaluate safety, tolerability, and potential anti-tumor effects.

Advanced Solid TumorsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Preclinical Alzheimer's Disease: JNJ-64042056 Immunotherapy

We are studying a new treatment to see if it may help slow cognitive decline in people with preclinical Alzheimer's disease. Participants will receive either the treatment or a placebo to compare effects.

Preclinical Alzheimer's Disease>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesNeurologyPsychiatry

UDCA for Visual Recovery After Retinal Detachment Surgery

We are studying whether UDCA can improve vision recovery in patients who have had surgery for retinal detachment. The trial also looks at the treatment's safety and other effectiveness measures.

Rhegmatogenous Retinal Detachment≤3 monthsConfirmation phase (III)Standard MedicinesOphthalmology

Lung Cancer: Avutometinib and Sotorasib Study

We are testing a combination of two medications for patients with KRAS G12C mutant non-small cell lung cancer. The goal is to find the best dose and see how well it works and how safe it is.

Non-small Cell Lung CancerSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Tocilizumab for Acute Chest Syndrome in Sickle Cell Disease

We are studying whether tocilizumab can help patients with sickle cell disease recover from acute chest syndrome faster and safely. The trial includes both children and adults to assess its effectiveness and safety.

Sickle Cell Disease>2 yearsConfirmation phase (III)Standard MedicinesHematologyPulmonology

Colorectal Cancer: ABBV-400 Treatment Study

We are studying a new drug, ABBV-400, combined with standard treatments for adults with advanced colorectal cancer. The goal is to assess its safety and effectiveness in patients who have already been treated.

Metastatic Colorectal CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Uveitis Treatment: Adalimumab vs. Mycophenolate Mofetil

We are studying whether adalimumab can improve outcomes for people with steroid-dependent non-infectious uveitis compared to the standard treatment. This trial will help us understand the effectiveness and safety of both medications.

Uveitis>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementOphthalmologyRheumatology

Cholestyramine for Obese Women: Pollutant Levels Study

We are exploring how cholestyramine treatment impacts harmful pollutant levels in obese women who may undergo bariatric surgery. This study aims to understand its effects before and after the surgery.

Epidermolysis Bullosa≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesDermatologyEndocrinologyInternal Medicine

IVF Luteal Phase Support: GnRH Agonist vs. hCG

We are studying whether a GnRH agonist can improve live birth rates and reduce miscarriages in women undergoing IVF compared to traditional hCG and progesterone support.

Assisted Reproductive Technology≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesGynecology and Obstetrics

Childhood Onset Nephrotic Syndrome: Obinutuzumab vs. MMF

We are studying whether obinutuzumab is more effective and safer than MMF for children with childhood onset idiopathic nephrotic syndrome. We will also look at how these treatments affect fatigue and quality of life.

Childhood Idiopathic Nephrotic Syndrome1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Efruxifermin for Non-Cirrhotic NASH/MASH

We are studying whether Efruxifermin can improve liver health and reduce fibrosis in people with Non-Cirrhotic NASH or MASH. Participants will be compared to those receiving a placebo to assess safety and effectiveness.

Non-alcoholic Fatty Liver DiseaseHepatic Fibrosis1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesEndocrinologyHepatology

S. aureus Bacteremia: Cloxacillin Dosing Study

We are investigating whether kidney function can help identify patients who may need adjusted doses of cloxacillin. This study aims to ensure safer and more effective treatment for those with S. aureus bacteremia.

Staphylococcus aureus BacteremiaMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesNephrology

Innovative Cell Therapy for Autoimmune Xerostomia

We are studying a new treatment using fat-derived cells for patients with autoimmune xerostomia. The goal is to see if it can improve symptoms and is safe to use.

Autoimmune Xerostomia1-2 yearsSafety phase (I)Efficacy phase (II)OtolaryngologyRheumatology

Pyridoxine for Primary Sclerosing Cholangitis

We are studying whether pyridoxine can lower liver enzyme levels in people with primary sclerosing cholangitis. The trial will also look at its effects on vitamin B6 levels, liver function, and quality of life.

Primary Sclerosing Cholangitis≤3 monthsEfficacy phase (II)Standard MedicinesGastroenterologyHepatology

Spinal Muscular Atrophy: Risdiplam for Children

We are studying the effectiveness and safety of risdiplam in children with spinal muscular atrophy who have not improved after gene therapy. This research aims to see if risdiplam can help these patients regain function.

Spinal Muscular Atrophy (SMA)>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Metastatic Colorectal Cancer: Targeted Therapies Study

We are evaluating the safety and effectiveness of new targeted treatments for patients with metastatic colorectal cancer. This study aims to find better options for specific groups of patients.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)Oncology

Non-Small Cell Lung Cancer: Fianlimab and Cemiplimab with Chemotherapy

We are studying if adding Fianlimab to Cemiplimab and chemotherapy is safer and more effective for adults with early-stage non-small cell lung cancer that can be surgically removed. This trial will help us understand the best treatment options for these patients.

Resectable Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)16-20 visitsStandard MedicinesCost ReimbursementPartially RemoteOncology

Duchenne Muscular Dystrophy: GNT0004 Gene Therapy

We are testing a new gene therapy for boys with Duchenne Muscular Dystrophy who can walk. The study aims to find the right dose and evaluate the therapy's safety and effectiveness compared to a placebo.

Duchenne Muscular DystrophySafety phase (I)Efficacy phase (II)Investigational MedicinesInternal MedicineNeurologyPediatrics